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ARENA-SHEAP 
Statistical and health economic analysis 
plan 
 
This document describes the analytical strategy for the ARENA trial study. 
It has been developed by  
Dr Erik Lenguerrand (Medical Statistician) 
Dr Elsa Marques (Health Economist) 
Dr Neil Artz (Clinical Lead)  
Dr Vikki Wylde (Chief Investigator) 
on behalf of the ARENA research team. 
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I. Data cleaning and quality control checking 
An ongoing data quality checking process will be implemented throughout the course of the 
trial. For the first 25 recruited patients, a double-data entry exercise will be conducted for all 
the information already imputed in the database.  During the trial, a random sample of 5 
patients will be selected at regular intervals and all their completed questionnaires will be 
double-entered.  Fields with the highest errors frequencies will be identified and appropriate 
actions implemented including re-training staff.  
Continuous double data entry of pre-operative and 12 months post-operative LEFS and EQ-
5D will be conducted for each patient once their 12 months questionnaire has been 
completed. 
During the trial, research nurses, the trial manager and trial administrative support staff 
reviews responses to the questionnaires. When questions are incomplete or the patients fail to 
return the questionnaires, research staff follows patients up with a telephone call. During this 
telephone call, research staff queries missing responses to the questionnaire. For non-
returners, research staff delivers a shorter version of the full follow-up form which includes 
only the primary clinical outcome tool (LEFS) and the primary economic result tools (EQ-5D 
and resource use questionnaire). 
Towards the end of the trial (months 23-27), a thorough data cleaning exercise will be 
conducted. The fields of interest for the analyses presented in section II, III and IV will be 
investigated to identify 1.incomplete items, 2.implausible values and if relevant 
3.inconsistencies across measurement points/questionnaire.  
For categorical variables, if participants put a mark outside the box associated with one item 
(category), the closest box will be assigned. If two boxes are marked, that which indicates the 
more severe problem will be chosen. 
Categorical/binary variables will be tabulated to identify implausible coding/categories and 
missing items. The database should tag all the fields not completed by the participants, 
allowing the identification of fields accidentally missed during the data inputting process. For 
missing items and implausible code, the original data will be checked on the completed 
questionnaires/case report forms and any data entry errors corrected. In case of incertitude, 
the Chief Investigator/trial manager and study statistician/ health economists will take a 
collegial decision to amend the field appropriately. For remaining implausible values, a 
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variable that indicates ‘possible implausible value of X’ (where X is the name of the variable 
that has a possible implausible value) will be derived and the implausible value in X will be 
discarded. 
 
Continuous variables will be investigated with histograms, box and/or normal plots. Values 
that appear outside of the main distribution in the majority of participants (i.e. outliers) on 
normal plots and histograms, as well as outside the “whiskers” of the box plot will be 
considered implausible. For implausible values, the original data will be checked on the 
completed questionnaires/case report forms and any data entry errors corrected. In case of 
incertitude, the Chief Investigator/trial manager and study statistician will take a collegial 
decision to amend the field appropriately. For remaining implausible values, a variable that 
indicates ‘possible implausible value of X’ (where X is the name of the variable that has a 
possible implausible value) will be derived. In the primary and secondary effectiveness 
analyses we will complete analyses with all participants included (including where they have 
a possible implausible value) and again with participants excluded for analyses with a given 
outcome if their value for that outcome has been marked as possibly implausible. If removal 
of participants with possible implausible values results in a change of a magnitude that would 
affect the interpretation/conclusion for that outcome then both sets of results will be reported; 
otherwise only the results with all included irrespective of ‘implausible value’ status will be 
reported. 
Composite scores derived by adding/combining discrete questionnaire items (see following 
section) will be investigated in a similar manner as continuous variables. We do not expect 
implausible total scores as the logical rules implemented in the data entry forms should 
prevent such a situation. However, if this were to be encountered, scores outside the expected 
range will be considered as implausible and discarded.   
The cost-effectiveness analyses will follow the effectiveness analyses in terms of participants 
excluded and will use the outcome values derived in the effectiveness analyses to compute its 
results. For resource use categories, we will investigate both the range of values reported and 
the patterns of missing data per time point. Implausible very high or negative values will be 
first checked against the primary data collection source (questionnaire or case report form); 
and then checked against patterns of the same or related resource use categories and 
sociodemographic variables. If values are still deemed implausible on final check, they will 
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be discarded. Discarded values would therefore be considered missing values and completed 
using multiple imputation methods (see section IV.f.).  
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II. Deriving the primary and secondary outcomes  
a. Lower Extremity Functional Scale (LEFS) 
The primary outcome is the LEFS, a composite score derived by summing together 20 Likert-
scale type items. Those items relate to four different groups of activities: Hardest Activities, 
Moderately Difficult Activities, Moderately Easy Activities and Easy Activities (see table 
below extracted from Stratford PW, Hart DL, Binkley JM, Kennedy DM, Alcock GK, Hanna 
SE: Interpreting Lower Extremity Functional Status Scores. Physiother Can 2005, 57(2):9. ) 
Each item ranges from 0 (extremely difficult) to 4 (no difficulty) and the total score ranges 
from 0 (high disability) to 80 (no disability). Up to 4 missing item responses are permitted to 
derive the total score.  
 
The guidelines for handling missing items are as follows:  
1. A minimum of 16 items must be answered to use the LEFS 
 2. No more than two missing items can come from any one of the groups reported in Table 2.  
3. To impute an item score, average the item values provided by the patient for the two 
closest items identified in the item hierarchy in Table 2.  
4. If the most difficult item response (running on uneven ground) is missing, assign the score 
of the closest answered item. 
 5. If the easiest item response (walking between rooms) is missing, assign the score for the 
closest answered item.  
To illustrate these steps, suppose that a patient left the item "getting in or out of the bath" 
blank. One would impute a value for this item by averaging the responses for "getting in or 
out of a car" and "performing light activities around the home." Thus, if the respective scores 
were 3 and 2, the imputed item score would be 2.5. 
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This is a score in whole numbers and will be treated as a continuous variable. 
b. Knee injury and Osteoarthritis Outcome Score (KOOS) 
The KOOS is a secondary outcome. It consists of 5 subscales; pain, other symptoms, function 
in daily living (ADL), function in sport and recreation (Sport/Rec) and knee related quality of 
life (QOL). Standardized answer options are given (5 Likert boxes) and each item is assigned 
a score from 0 (none) to 4 (extreme). A normalized score (100 indicating no symptoms and 0 
indicating extreme symptoms) is calculated for each subscale:  
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As long as at least 50% of the subscale items are answered for each subscale, a mean score 
can be calculated. If more than 50% of the subscale items are omitted, the response is 
considered invalid and no subscale score should be calculated. For the subscale Pain, this 
means that 5 items must be answered; for Symptoms, 4 items; for ADL, 9 items; for 
Sport/Rec, 3 items; and for QOL, 2 items must be answered in order to calculate a subscale 
score. Subscale scores are independent and can be reported for any number of the individual 
subscales, i.e. if a particular subscale is not considered valid (for example, the subscale 
Sport/Rec 2 weeks after total knee replacement), the results from the other subscales can be 
reported at this time-point. 
A total score has not been validated and is not recommended. For the purpose of an RCT, 
KOOS subscale scores can be aggregated and averaged as a primary outcome. For the 
purpose of this trial, we will investigate the averaged KOOS and the five individual KOOS 
subscale scores to enable clinical interpretation. If any subscale scores are missing, the 
averaged score will not be derived.  
These are scores in whole numbers and will be treated as continuous variables. 
c. HADS 
The HADS is a secondary outcome. It is comprised of two subscales: Depression and 
Anxiety. Each sub-scale is derived by summing together 7 Likert-scale type items. Items are 
rated on a 4-point Likert-type scale ranging from 0 to 3, with higher scores representing 
greater symptom severity. Each subscale has a score ranging from 0 to 21.  
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It is recommended that the score for a single missing item from a subscale is inferred by 
using the mean of the remaining six items. If more than one item is missing, then the subscale 
should be judged as invalid. We will therefore considered the subscale as missing if more 
than one item is missing.  
These are scores in whole numbers and will be treated as continuous variables. 
d. Self-Administered Patient Satisfaction Scale for Primary Hip and Knee 
Arthroplasty  
The Patient Satisfaction Scale is a secondary outcome. It is comprised of four items. Each 
item is scored on a 4-point Likert scale with response categories consisting of very satisfied 
(100 points), somewhat satisfied (75 points), somewhat dissatisfied (50 points), and very 
dissatisfied (25 points). The scale score is the unweighted mean of the scores from the 
individual items, ranging from 25 to 100 per item (with 100 being most satisfied). 
There is no published recommendation on how to handle missing item information. We will 
therefore consider the satisfaction scale as missing is any item is missing.  
This is a mean score with continuous values between 25 and 100 and will be treated as a 
continuous variable. 
An unvalidated single-item satisfaction outcome is also considered to assess the satisfaction 
with the physiotherapy received by both groups of participants. Based on a 5-item Likert 
scale ranging from very satisfied (1) to very dissatisfied (5), this variable describes 
satisfaction with physiotherapy treatment.  This is a categorical variable and will be treated as 
an ordinal variable. 
e. EQ-5D 
The EQ-5D-5L response profiles will be combined using weights from the EuroQol’s 
published UK societal utility tariffs to produce a composite quality of life score at every time 
point (2-weeks, and 3-, 6-, and 12-months post-operative) for each patient. These quality of 
life, or “utility” scores, are used to derive quality adjusted life years, or QALYs. 
The EQ-5D-5L QoL scores will be treated as continuous variables and are limited at a 
maximum of 1 (corresponding to perfect health), where 0 corresponds to death. Negative 
values are permitted (worse than death). 
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In economic evaluation, outcomes, such as the QALY, should be jointly imputed with costs. 
A QALY in this study will be computed based on the 5 domains of the EQ-5D-5L 
administered over 4 time points, for a total of up to 20 variables. If any of the 5 items within 
the EQ-5D-5L are missing, the utility score will be recorded as missing in a separate indicator 
variable, per time point, per patient. In section V.f. “Dealing with missing data” we explore 
strategies to deal with EQ-5D-5L missing data.  
f. Resource use categories 
For resource use categories, the range values reported per time point will be investigated. We 
will look at patterns of missing data per time point. Implausible high values will be rounded 
to the maximum possible value within the period of resource use data collection; or discarded 
if the pattern of missing data for a particular resource category is unclear. Discarded values 
would therefore be considered missing values and completed using multiple imputation 
methods. 
Research data entry staff noted patterns of missing or poorly completed data during data entry 
of resource use questions which prompted telephone checks. The format of resource use 
questions was amended March 2017 to improve self-completion. This review also prompted a 
question on admission to nursing or rehabilitation homes to be separate from other secondary 
care admissions. A field in the database will be created to distinguish between patients 
completing versions before and after this format change. We will check patterns of 
completion for the questions before and after the format changes. If more data is reported 
after the change in a substantial number of cases, we will decide between: 
-  excluding this category for economic analysis,  
- imputing the data in the initial version if the imputation model can efficiently 
estimate this, 
- consider all data as is, if not likely to bias or impact results. 
Methods to deal with missing data, including the multiple imputation model are detailed in 
section IV.f. “Dealing with missing data”. Imputation models for resource use and outcome 
variables can be very complex and adding layers of complexity may not be efficient. 
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III. Effectiveness analyses 
a. Participant flow 
 A CONSORT diagram will summarise participant flow through the trial, documenting 
invitation and recruitment, receipt of intervention or usual care as allocated, and collection of 
data (pre-operatively, during the 12 weeks following surgery and  at 3 months, 6 months, and 
12 months post-operatively). We will define the recruitment rate as the percentage of eligible 
patients who are recruited and successfully randomised.  
 The number and percentage of participants who withdraw, with and without primary 
outcome data, at each of the follow-up stages will be reported for each trial group 
(intervention or usual care) and compared using chi-squared of Fisher-exact tests.  
b. Comparison of baseline characteristics  
We will compare relevant summary statistics of baseline characteristics between participants 
allocated to the intervention group and usual care group in order to determine whether any 
potentially influential imbalance has occurred (by chance) between these two groups. We will 
focus on demographic, surgical and stratification variables, as well as outcome measures at 
baseline. 
The comparisons between the two groups will be made by summarising variables in each 
group (intervention versus usual care groups). For all continuous and score variables we will 
check distributions using histograms and normal plots to examine how close to normality 
these are before deciding which summary statistics to present.  Continuous variables with 
approximately normal distributions will be presented as means and standard deviations (SD).  
Continuous variables that we anticipate will not have an approximate normal distribution will 
be presented as medians and interquartile ranges (IQR).  Binary/categorical variables will be 
presented as number (n=) and percentage (%).  
We will not compare baseline characteristics between the two groups with a statistical test (p-
value) as any low values simply represent a type-1 error under the assumption that we have 
adequately randomly allocated participants.  
c. Primary analysis and related analyses 
The primary outcome is the LEFS score measured at 12-months post-operative. This study 
has been designed and powered to detect a difference equivalent to a minimal clinically 
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important difference of 9 scale points between the two groups with a power of 80%, a two-
sided 5% significance level and accounting for up to 35% missing data. 
i. Intention-to-treat analysis and dealing with missing primary outcome data  
The primary analysis will be conducted on an intention-to-treat (ITT) basis with due 
emphasis placed on the confidence interval for the between-group comparison when 
comparing the primary outcome for the two groups (intervention versus usual care groups).  
ITT requires all participants in a clinical trial to be included in the main analyses in the 
groups to which they were randomised. Compliance with the ITT principle requires a strategy 
to handle loss to follow-up or missing data on primary outcome at follow-up amongst those 
who have been randomised.  
The primary analysis will be based on all randomised participants with available LEFS 
outcomes scores at at least one post-operative assessment point. In other words, the analysis 
will include patients with LEFS scores available at every post-operative follow-up 
assessments, patients with scores available only at the 18 months assessment (primary 
outcome) and those with missing primary outcome but at least one other post-operative 
assessment. The data will be analysed with multilevel linear regression, a likelihood-based 
method which will provides an unbiased estimate of the intervention effectiveness (at 18 
months) by including all available post-randomisation data for participants with missing 
primary outcome data.1 This approach relies on the data being missing at random (MAR)and 
does not include the randomised patients with no post-operative LEFS measures at any post-
operative time point.  
To include all randomised participants in respect with the ITT principle we will also use a 
multiple imputation strategy (chained equations). The imputation process will be stratified by 
trial group. The number of imputation sets will be determined by the number of patients with 
missing outcomes. For example, if 14% of patients have missing LEFS at 12-months, 14 
imputations will be performed. The variables used on the imputation process will be the 
LEFS scores measured at 3-, 6- and 12-months post-operative, the stratification variables (the 
pre-operative LEFS and a factor identifying the recruitment centre), the imbalanced baseline 
characteristics between trial groups used in the adjusted model, and relevant ancillary 
variables. The ancillary variables will consist of the baseline comorbidities, surgical and 
socio-demographics characteristics which differ between participants with complete and 
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missing primary outcome.(The selection process of these ancillary variables will also identify 
the pattern of randomness (MAR or Missing Completely At Random) of the studied data). 
The Rubin’s rules will be used to combine the resulting multiple imputed estimates. This 
strategy relies on the MAR hypothesis. 
The following strategies will also be used to assess the sensitivity of the above results to 
departures from MAR as described by White et al. 1, 2, 3. The mean of the unobserved 
responses for LEFS at 12 months will be considered to be 10% worse than the mean of the 
observed responses (irrespective of randomised group). We will also assumed that the data 
will be informatively missing only in the intervention arm, with the mean of the unobserved 
responses being as much as 10% more and then 10% less than the mean of the observed 
responses, and comparable between unobserved and observed responses in the control group. 
Patients who withdraw will not be considered in the analyses.  
i. . Primary analysis (LEFS at 12 months post-operative) 
The primary outcome, the LEFS at 12 months post-operative, is a score treated as a 
continuous variable. We will first use a normal plot and a histogram to assess the normality 
of this measure. If the outcome is approximately normally distributed, the raw score will be 
used with no transformation. If important departure from the normal distribution is observed, 
we will explore transforming the score to improve the normality of the residuals in the 
regression model. The decision to transform the score or not, and if so which transformation 
to use, will be decided by considering: (1) the distribution of the variable, (2) the distribution 
of residuals from regression models, (3) the ease of interpreting results following any given 
transformation compared with no transformation and (4) whether main results/conclusions 
are influenced by the transformation or not. If the overall conclusion is not altered by whether 
the variable is transformed or not, we would use the untransformed (easier to interpret) 
outcome. 
We will use a linear mixed regression to model the difference in means LEFS scores between 
participants allocated to the intervention group and those allocated to the usual care group  
(reference group),whilst taking account of clustering induced by the repeated measures within 
patients. We will model the LEFS scores measured at 3-, 6- and 12-months. As described in 
1. Including all individuals is not enough: lessons for intention-to-treat analysis. White IR, Carpenter J, Horton NJ. Clin Trials. 2012 
Aug;9(4):396-407. doi: 10.1177/1740774512450098. 
2.Strategy for intention to treat analysis in randomised trials with missing outcome data. White IR, Horton NJ, Carpenter J, Pocock SJ. 
BMJ. 2011 Feb 7;342:d40. doi: 10.1136/bmj.d40. 
3. Allowing for missing outcome data and incomplete uptake of randomised interventions, with application to an Internet-based alcohol 
trial.White IR, Kalaitzaki E, Thompson SG. Stat Med. 2011 Nov 30;30(27):3192-207. doi: 10.1002/sim.4360. .  
ARENA trial 2017 
 
ARENA SHEAP version 1, 07/09/2017 Page 15 
 
section III.C.i, this model allows the production of estimates which are valid under the MAR 
hypothesis and therefore avoids imputing the outcomes for those with missing information 
whilst complying with the ITT principle. The model will be adjusted for the stratification 
variable used in the randomisation, i.e. the pre-operative LEFS score (model as a continuous 
variable) and a factor identifying the recruitment centre (Southmead vs Emerson Green). 
The main model will be 
𝑌𝑖𝑗 = 𝛽0 + 𝛽1𝑋1𝑖𝑗 + 𝛽2𝑋2𝑖𝑗 + 𝛽3𝑋3𝑖𝑗 + 𝛽4𝑋1𝑖𝑗𝑋2𝑖𝑗 + 𝛽5𝑋1𝑖𝑗𝑋3𝑖𝑗 + 𝛽6𝑋6𝑖𝑗 + 𝛽7𝑋7𝑖𝑗 + 𝑢0𝑗 + 𝑒0𝑖𝑗 
Where  
𝑌𝑖𝑗 is the LEFS outcome at time i=1(3 months post-operative), 2(6 months post-operative) or 
3(12 months post-operative) for participant j=1…256.  
𝛽0 is the intercept, i.e. the outcome at 12 months amongst those in usual care group, operated 
on at Southmead Hospital, with the lowest level of pre-operative LEFS score. 
𝛽1 is the intervention effect, i.e. the mean difference in LEFS outcome at 12 months 
comparing participants in the intervention group to those in the usual care group (reference), 
having adjusted for recruitment centre, pre-operative LEFS score and taking into account the 
non-independence amongst measurements from the same participant (repeated 
measurements). 𝑋1𝑖𝑗 is the factor coded 1 if the participant received the intervention, 0 if the 
participant had only the usual care (reference). In the primary analysis, the focus will be only 
on this estimate, its 95%CI interval and p-value.  
𝛽2 and 𝛽3 are respectively the effect associated with 3 months 𝑋2𝑖𝑗 and 6 months 
𝑋3𝑖𝑗 assessment points covariables among participants in the usual care group, i.e. the mean 
difference in LEFS outcome between respectively the 3 months and 12 months LEFS scores 
and then between the 6 months and 12 months scores among participants in the usual care 
group. The 12 months assessment point is used as the reference and not model per se in the 
equation.  
𝛽4  and 𝛽5 are the interaction coefficient for the interaction of the intervention indicator with, 
respectively, the 3 months or 6 months assessment points covariables. Those parameters will 
be used to identify the intervention effect at 3 months and 6 months.  
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𝛽6 and 𝛽7 are the effects associated with the stratifying covariables 𝑋6𝑖𝑗and 𝑋7𝑖𝑗, respectively 
the LEFS pre-operative score and the recruitment centre(Southmead Hospital as a reference). 
𝑢0𝑗 is the residual of the outcome for participant j. 
𝑒0𝑖𝑗 is the residual of the outcome for measurement i of participant j. 
For the effect associated with 𝛽1, statistical significance will be indicated by a two-sided p-
value of ≤ 0.05.  
ii. Sensitivity analyses 
Different sensitivity analyses will be conducted. 
The first analysis will investigate the impact of clustering of outcome by surgeon that 
performed the operation on the intervention effect at 12 months, i.e the amount of outcome 
variability explained at surgeon level rather than individual level. A third level (patients 
nested within surgeon) will be added to the equation presented in the previous section. If the 
variance of the random effect associated with surgeon level is significant, this level will be 
kept for the following sensitivity analyses; otherwise the two-level model presented in the 
previous section will be used.  
The following analysis will adjust the intervention effect for any baseline imbalanced 
participant characteristics. Given the published differences in outcomes after TKR for men 
and women, exploratory analysis will be undertaken to investigate the impact of gender, i.e. 
the analysis will be first adjusted for gender and the interaction between the intervention 
effect and gender will then be explored. The trial is not powered for such adjustments and it 
will only inform us on their potential impact on the intervention effect.  
The main analysis as well as the above sensitivity analysis will be replicated using the 
different scenarios to handle missing LEFS outcome presented in section III.c.i.. 
Finally the main and adjusted sensitivity analyses (without imputation) will be performed 
using a per-protocol (PP) approach. Participants randomised to the intervention group and 
who attended less than 4 intervention sessions (<4) will be considered as non-compliant. 
They will be modelled in the group they were randomised to for the ITT-analyses but will be 
excluded from the PP models. We do not anticipate that patients allocated to the usual care 
group will attend intervention session but if this were the case (at least four sessions), they 
would still be modelled in the control group for the ITT-analyses but would be excluded from 
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the PP models. Further exploratory analyses will be conducted to investigate how change in 
the number of attended session(s) used to define the threshold for intervention adherence will 
affect the results. 
For the adjusted sensitivity analyses, the adjustment covariates with missing information will 
be handled using the missing indicator strategy4: In addition to the covariate of interest, an 
indicator variable (indicating whether a baseline covariate is missing or observed) will be 
introduced in the equation presented above together with imputing the missing covariate with 
a ‘temporary’ value derived from the observed baseline covariate values (usually the mean). 
The adjustment covariates with missing information will also be imputed chained equations 
in the multiple imputation model described in section III.c.i. 
iii. Additional analyses 
If no transformation of the LEFS score at 12 months post-operative provides an 
approximately normally distributed outcome and regression residuals, the main analysis 
presented above will be reported, i.e. the raw LEFS outcome will be modelled with the linear 
mixed regression described above. The resulting intervention effect will be contrasted with 
the following results: 
-The LEFS median score at 12 months and interquartile-range will be presented by trial group 
and compared with a Wilcoxon-Mann-Whitney test.  
-The LEFS outcome will be transformed into an ordinal dependent variable and modelled 
with a multilevel ordered logistic regression or a multilevel generalized ordered logit model. 
At the time of writing this SHEAP there is no clear guidance on how to categorise the LEFS 
outcome. We propose to use the following categories: 
[0-20], [21-40], [41-60], >60. That categorisation will be revisited if new guidance are 
published before the end of this trial. The final choice of categorisation will be approved by 
the Trial Steering Committee who will consult an external statistician to validate the decision. 
The model will provide a sets of odd-ratios associated with the intervention effect:  
-comparing the odd of having a LEFS score of {[0-20]} vs the odds of having a LEFS score 
of {[21-40], [41-60], >60} for those who received the intervention vs those who did not 
- the odd of having a LEFS score of {[0-20] , [21-40]} vs the odds of having a LEFS score of 
 4. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. 
Groenwold RH, White IR, Donders AR, Carpenter JR, Altman DG, Moons KG. 
CMAJ. 2012 Aug 7;184(11):1265-9. doi: 10.1503/cmaj.110977 
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{ [41-60], >60} for those who received the intervention vs those who did not 
- the odd of having a LEFS score of  {[0-20] , [21-40],[41-60] } vs the odds of having a 
LEFS score of {  >60} for those who received the intervention vs those who did not 
We will also investigate the influence of additional physiotherapy treatment received by 
participants. The main analysis will be adjusted for use of additional physiotherapy.  
Similarly, although each physiotherapy class will be delivered by two physiotherapists, the 
physiotherapists delivering the classes are likely to vary. In an exploratory analysis, we will 
investigate if the mean/median LEFS score at 12 months post-operative differed according to 
the lead physiotherapist in charge of the attended intervention sessions. As participants could 
be supervised by several physiotherapists through the course of their 6 sessions, they will be 
related to the lead physiotherapist who will have delivered most of their sessions. If any 
difference in LEFS mean/median between physiotherapists is identified, these evidences will 
be used to discuss the intervention effect assessed in the main analysis.   
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iv. Secondary analyses 
LEFS 3 months and 6 months post-operative 
Using the same models presented below, we will estimate the intervention effect on LEFS at 
3 months and 6 months, respectively 𝛽1 + 𝛽4 and  𝛽1 + 𝛽5. We will also determine if: 
• the intervention effect at 3 months differs from the intervention effect at 12 months: 𝛽4; 
• the intervention effect at 6 months differs from the intervention effect at 12 months: 𝛽5;  
• the intervention effect at 3 months differs from the intervention effect at 6 months: 𝛽5 −
𝛽4 
We will focus on the 95% CI and p-values associated with coefficients or linear 
combinations.  
KOOS 
The KOOS subscales will be collected pre-operatively, and at 3 months, 6 months and 12 
months post-operatively. They are scores and will be treated as continuous outcomes.  
Similar to the LEFS scores, those outcomes will be modelled with a linear mixed model. The 
effect of the intervention on the 5 KOOS sub-scales and on the average total KOOS score 
will be investigated in separate analysis sets, i.e. 6 different sets of analysis in total. 
The strategy to handle missing outcomes will be similar except that each KOOS subscale and 
the average total KOOS score will be imputed with separate process. The multiple imputation 
strategy will use the post-operative KOOS scores rather than the post-operative LEFS scores 
to impute missing scores and will also use the pre-operative KOOS score in addition to the 
pre-operative LEFS score and relevant baseline comorbidities and socio-demographics 
characteristics.   
A similar modelling strategy as the one presented above for the LEFS score will be used: 
-First, an ITT-regression similar to the main analysis for the primary outcome but further 
adjusted for 𝛽8𝑋8𝑖𝑗, the pre-operative KOOS sub-scale score/ average total KOOS score; 
-the ITT-adjusted model; 
-the different sensitivity analyses for handling missing outcome 
-the main analysis and adjusted analyses will be repeated on a PP-basis. 
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The raw scores will be modelled but if required appropriate transformation will be 
considered. If no suitable transformation is found, the scores will be categorised using 
appropriate thresholds according to published and accepted evidences and in the absence of 
such evidences we will consider the following classification: [0-25], [26-50], [51-75],>75. 
The final choice of categorisation will be approved by the Trial Steering Committee who 
will consult an external statistician to validate the decision. 
We will first focus on the intervention effect on KOOS at 12 months, then at 3 and 6 months 
and then consider the difference in intervention effect between each measurement point as 
described previously for the LEFS scores.  
HADS 
The HADS subscales will be collected pre-operatively, and at 3 months, 6 months and 12 
months post-operatively. They are scores and will be treated as continuous outcomes.  A 
similar modelling strategy as for LEFS and KOOS scores will be considered using linear 
mixed regressions. Two sets of analyses will be conducted; one for each subscale of the 
HADS. 
The strategy to handle missing outcomes will be similar except that each HADS subscale will 
be imputed with separate process. The multiple imputation strategy will use the post-
operative HADS scores rather than the post-operative LEFS scores to impute missing scores 
and will also use the pre-operative HADS subscale score in addition to the pre-operative 
LEFS score and relevant baseline comorbidities and socio-demographics characteristics.   
The analyses will be further adjusted by 𝛽8𝑋8𝑖𝑗, the pre-operative HADS subscale score (the 
pre-operative KOOS scores will not be considered in the analyses of HADS subscale scores). 
The raw scores will be modelled but if required appropriate transformation will be 
considered. If no suitable transformation is found, the scores will be categorised using the 
following published thresholds:  [0-7], [8-10], [11-21]. If the sample size in category [11-21] 
is not large enough, categories [8-10] and [11-21] will be collapsed. 
We will first focus on the intervention effect on HADS at 12 months, then at 3 and 6 months 
and then consider the difference in intervention effect between each measurement point as 
described previously for the LEFS scores.  
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Satisfaction with knee replacement and physiotherapy treatment  
The satisfaction with surgery score will be collected at 3-months, 6-months and 12-months 
post-operatively and will be treated as a continuous outcome.  A similar modelling strategy as 
for LEFS scores will be considered using linear mixed regressions.  
The strategy to handle missing outcomes will be similar as for LEFS scores. The multiple 
imputation strategy will use the post-operative satisfaction with surgery score rather than the 
post-operative LEFS scores to impute missing scores and will use the pre-operative LEFS 
score and relevant baseline comorbidities and socio-demographics characteristics.   
The analyses will not be further adjusted by a pre-operative score as this is irrelevant for this 
outcome.  The raw scores will be modelled but if required appropriate transformation will be 
considered. If no suitable transformation is found, the scores will be categorised using the 
following published thresholds:  [25-50], [51-75],>75.  
The satisfaction score with the physiotherapy received is an ordinal variable also collected in 
each post-operative questionnaire. It will be considered with a multilevel ordered logistic 
regression or a multilevel generalized ordered logit model (depending how the hypothesis of 
proportional odds-ratio hypothesis holds true). A similar modelling strategy as for the above 
outcomes will be considered.  
The multilevel ordered logistic model will be 
𝑙𝑜𝑔𝑖𝑡{Pr (𝑌𝑖𝑗 > 𝑠|𝑋𝑖𝑗 , 𝑢0𝑗)}  
= 𝛽1𝑋1𝑖𝑗 + 𝛽2𝑋2𝑖𝑗 + 𝛽3𝑋3𝑖𝑗 + 𝛽4𝑋1𝑖𝑗𝑋2𝑖𝑗 + 𝛽5𝑋1𝑖𝑗𝑋3𝑖𝑗 + 𝛽6𝑋6𝑖𝑗 + 𝛽7𝑋7𝑖𝑗 + 𝑢0𝑗 − 𝐾𝑠 
Where 𝑌𝑖𝑗is the ordinal outcome with S ordinal categories denoted s (S=1,..,5). The observed 
ordinary satisfaction variable 𝑌𝑖𝑗is generated from the latent continuous response 𝑦𝑖𝑗
∗  via a 







1  𝑖𝑓          𝑦𝑖𝑗
∗ ≤ 𝐾1  
2 𝑖𝑓 𝐾1 < 𝑦𝑖𝑗
∗ ≤ 𝐾2 
3 𝑖𝑓 𝐾2 < 𝑦𝑖𝑗
∗ ≤ 𝐾3
4 𝑖𝑓 𝐾3 < 𝑦𝑖𝑗
∗ ≤ 𝐾4
5 𝑖𝑓  𝐾4 < 𝑦𝑖𝑗
∗            
 
 Where 𝐾𝑠are the category-specific thresholds (i.e. the category of the variable);  
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Where the 𝑢0𝑗 is a patient-specific random intercept, the overall level or intercept of the 
cumulative logits which varies over patients j; 
And where the 𝛽 and 𝑋 have the same meaning as previously.  
We will first focus on the intervention effect on satisfaction with surgery or satisfaction with 
physiotherapy scores at 12 months, then at 3 and 6 months and then consider the difference in 
intervention effect between each measurement point as described previously for the LEFS 
scores.  
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IV. Cost-effectiveness analyses 
a. Objective 
To compare the physiotherapy intervention versus standard care in relation to costs and 
outcomes at 12 months after knee replacement surgery. 
b. Measurement of resources 
Resources used in relation to the delivery of the intervention will be recorded in study report 
forms. The physiotherapists delivering the sessions are asked to record time spent preparing 
and delivering the session, and the number of patients attending the session. The 
physiotherapist will also collect travel expenses for the patients attending sessions in a travel 
expenses form. These forms will collect information that will be used to value patients’ 
private travel expenses associated with the intervention. 
Resource use in relation to the knee replacement surgery, knee pain or knee function will be 
measured from randomisation until last follow-up. Resource use in relation to their knee 
surgery and function will be collected from patient self-completed questionnaires, completed 
at 3, 6 and 12 months after the knee replacement operation. Resources used within 2 weeks of 
the operation are not collected because randomisation occurred at 2 weeks; hence, no 
difference in resource use in relation to the intervention is expected between groups  
Patients are supplied with resource use logs at 2-weeks post operation (not analysed), to help 
them complete the subsequent questionnaires. Patient resource use is collected on the 
following categories: 
NHS resources 
a) inpatient and day case secondary care visits; 
b) A&E and outpatient visits, including hospital physiotherapy provided; 
c) community based NHS visits, such as GP and nurse visits; community physiotherapy 
and occupational therapy visits;  
d) medication use; 
e) occupational therapy; 
Personal Social Services 
a) food at home services; 
b) home care help services; 
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c) social worker contacts; 
d) equipment provided to patients and changes made to their homes.* 
* Note that some of equipment is provided by NHS occupational therapists at hospital discharge but 
paid by social services. On other occasions, these costs may be borne by the NHS. We will liaise with 
the finance department for both centres to confirm the nature of this resource use category for our 
patient group (NHS or PSS). 
 
Private expenses 
a) patient travel to the intervention;  
b) private healthcare or therapy; 
c) privately bought equipment; 
d) over-the-counter medication; 
e)  prescription charges; 
f) lost income. 
 
Productivity losses 
a) time off work; 
b) time off leisure activities; 
c) time spent on informal care by friend or family . 
c. Defining missing resource use categories 
Missing data for each resource use category will be explored per time point. Most questions 
in the resource use questionnaires have got indicator variables, for a patient to indicate 
whether they used a resource within the time period (YES/NO). If “Yes”, patients are asked 
to provide further details to allow for costing of the resource. If the indicator variable is 
missing or “No” but patients complete with plausible values the follow-up detail question, we 
will assume the indicator variable is “Yes”. If the patient indicates “Yes” but does not 
complete the detail follow-up question, data will be assumed missing. If both indicator 
variable and follow-up details are missing, the data will be considered missing, unless it is 
non-NHS resource use category with typically very poor completion rates, such as travel 
costs. In that case, we will take clinical advice and make a collegial decision on whether the 
data should be considered missing, zero, or plausible value assumed. 
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Patterns of missing data per patient over time will be assessed to ascertain whether the 
assumption of missing data or zero values is plausible, and assumptions will be re-evaluated 
otherwise. 
d. Valuation of resources 
Resource use collected to deliver the physiotherapy class will allow for a micro-costing 
approach to be taken.1 We will take a macro-costing approach for costing delivery of 
treatment in both arms otherwise. 
Resources in relation to the delivery of the intervention (such as staff grade and time, and 
resource use required to deliver care in both groups) will be valued using national UK tariffs 
(NHS reference costs2, PSSRU3, BNF4) where possible. Trust finance departments will be 
contacted for unit costs when national tariffs not available (e.g. cost of equipment used by 
patients). Productivity losses will be valued using a human capital approach and ONS 
averaged gross weekly wages per age group and gender. When national tariffs and finance 
procurement costs are unavailable, we will search for other available sources, such as 
comparable unit costs available in the literature, or online. Unit costs and their sources will be 
reported. Expenses incurred privately will be valued using generic unit costs if available, or 
self-reported expenditure otherwise. 
 
e. Estimation of costs and QALYs   
The cost associated with each resource use item will be calculated by multiplying the units of 
resource used in the 12-month period by its unit cost.  
Cost categories will be added by perspective: NHS, PSS, Private expenses and Productivity 
losses. These will be further grouped into NHS+PSS perspective for the primary analysis 
results and “Societal” perspective in a secondary analysis. When adding all cost categories 
for the societal perspective, we will deduct privately paid medications expenditure, and will 
use net wage rates to compute productivity losses and avoid double counting. The trial 
                                                          
1 Dakin H, Abangma G, Wordsworth S. What is the value of collecting detailed costing data in clinical trials? 
Trials, 2011, 12(Suppl 1) A42. 
2 Department of Health (2014) NHS reference costs 2013-2014, 
https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014 [accessed November 2015] 
3 Curtis L, Unit Costs of Health & Social Care 2014, Personal and Social Services Research Unit, 
2014, http://www.pssru.ac.uk/project-pages/unit-costs/2014/ [accessed November 2015] 
4 British National Formulary, British Medical Association and the Royal Pharmaceutical Society of Great Britain, 
London, [accessed November 2015] 
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research staff has focused their efforts into collecting NHS+PSS resource use. Our resource 
use questionnaire was not validated and there are generally noted difficulties for patients to 
understand and complete the nature of questions to collect private income and productivity 
losses. If private expenses and productivity losses are poorly completed, we may refrain from 
reporting these, or proceed with the analyses for the societal perspective results.  
Quality adjusted life-years (QALYs) accumulated will be calculated from the UK preference 
based utility scores using the area-under-the-curve approach: assuming a linear change 
between the time points (2 weeks and 3, 6 and 12 months). See section II for derivation of 
preference based utility scores from EQ-5D-5L responses. 
Cost and QALY estimates will be jointly determined in regression analysis, further adjusting 
by stratification variables, and baseline scores for QALYs. If feasible, and if the data 
distribution is non-normal, we will look at methodological ways to normalise the cost data.  
 
f. Dealing with missing data 
Economic evaluations that collect data using resource use questionnaires are prone to missing 
data. Cost is a compound variable adding all resource use units for each resource use 
category, recorded per time point. In this economic evaluation we will jointly impute cost 
categories and outcomes (QALYs and the primary clinical outcome: LEFS score).  
A QALY will be computed based on the 5 domains of the EQ-5D questionnaire administered 
over 4 time points. This generates 20 variables, with potential missing data requiring 
imputation. Using multiple chained equation methods to impute 20 EQ-5D variables along 
with multiple cost categories and other outcomes of interest (LEFS), may not be 
computationally feasible.  
We will investigate the feasibility of imputing EQ-5D domains within a multiple imputation 
model. Patterns of missing data in the domains of the EQ-5D will be examined. If the 
majority of patients only miss 1 domain, we will attempt to impute all 20 missing domains 
within the imputation model as this is likely to lead to more accurate imputation.5 If not 
computationally feasible, or if a majority of patients miss more than one domain, we will 
impute the whole utility score per time point.   
                                                          
5 Simons C L, Rivero-Arias O, Yu L M, Simon J, Multiple imputation to deal with missing EQ-5D-3L data: Should 
we impute individual domains or the actual index?, Quality of Life Research, 2015, 24(4) 805. 
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We will assess the plausibility of the assumption that cost data is missing at random – 
assuming that missing data may not be missing completely at random, but may depend on 
observed variables. Missing cost categories will be imputed, jointly with the EQ-5D and the 
LEFs scores. Other outcome measures will be excluded to ensure the imputation model is 
computationally feasible to run. We will follow the statistical analysis methodology for the 
imputation model. We will use multiple imputation methods, using chained equations, with a 
minimum of 20 sets, and predictive mean matching. Costs and outcomes are compounded 
over time and most cost categories are more efficiently estimated summed over the 12 
months period, rather than at time points. It may, therefore, not be feasible to keep the multi-
level structure within the multiple imputation model. Predictive mean matching will ensure 
imputed missing values exist in the observed data, avoiding implausible cost and utility 
values. The imputation models will be stratified by trial group (treatment or standard care), 
treatment centre, and controlled by minimisation variables and observed patient and surgical 
characteristics.  
For the main analysis, we will borrow complete LEFs scores from the statistical analysis to 
impute values for the EQ-5D and cost categories. In methodological sensitivity analysis, we 
will explore the effect of also imputing missing clinical outcome scores together with cost 
and utility values. Average cost and outcomes will be estimated using Rubin’s rules and 
bootstrapping. We will follow the most up to date guidelines on multiple imputation 
methodology will be followed.6 
 
g. Analysis 
The primary economic analysis will be a Cost-Utility Analysis (CUA) from an NHS and PSS 
perspective, and will include all costs incurred at 12-months post-operative. We will 
separately report private expenses and loss productivity. If feasible, a secondary analysis will 
be conducted from the societal perspective (i.e. including all costs to patient and society).  
Cost-Effectiveness Analyses (CEA) will also be carried out as secondary analyses, yielding 
cost per detected change in the LEFS score, from an NHS+PSS perspective, and use imputed 
values and intention to treat analysis in line with the primary economic analysis.  
                                                          
6 Faria R, Gomes M, Epstein D, White IR, A Guide to Handling Missing Data in Cost-Effectiveness Analysis 
Conducted Within Randomised Controlled Trials, PharmacoEconomics, 2014, 32(12) 193. 
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Costs will be adjusted for the stratification variables used in randomisation. QALYs will be 
adjusted for stratification variables and utility at 2-weeks post-operation in line with 
published guidance.7 The distributions for costs and outcomes will be investigated decide on 
methods for the independent regression analysis. We will use Seemingly Unrelated 
Regressions (SUR) to jointly estimate costs and outcomes. SUR methodology will also 
compute the correlation of residuals between the two models, and test if the two are 
independent or related. In other words, it will test if costs and QALYs are associated with 
higher or lower cost profiles for individuals, after adjusting for covariates. We will bootstrap 
costs and QALYs regression estimates with a minimum of 1,000 replications to account for 
uncertainty around the results and produce bootstrapped confidence intervals. 
Costs and QALYs are already measured and compounded over a period of time. The multi-
level mixed model approach for investigation of repeated measures is therefore not required 
for the economic result. However, should the primary statistical model use a multi-level 
mixed model approach to investigate the effects of surgeons or centres, the economic 
evaluation will also adapt to follow the statistical methodological approach.  
It is possible that not all costs and benefits accruing from the intervention are observed at 12 
months, if the intervention effects prolong to a longer term. We will investigate the difference 
in outcomes (LEFs score and QALYs) and costs from 2-weeks to 12-months post-operation 
in the two groups. While beyond the scope of the present analysis, we will assess whether it 
would be valuable to, in future research, modelling the extrapolation of the data after 12-
months.  
The cost-effectiveness results of this trial may be uncertain, due to structural or 
methodological uncertainty or sample size limitations. That is more so should the trial recruit 
fewer patients than expected. The economic analyses will have collected enough information 
to perform value of information analysis in a subsequent study to inform the decision to carry 
out further research, or provide evidence for decision-making based on the current trial 
results. 
 
                                                          
7 Manca A, Hawkins N, Sculpher MJ, Estimating mean QALYs in trial-based cost-effectiveness analysis: the 
important of controlling for baseline utility, Health Economics, 2005 14(5) 487. 
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h. Sensitivity analysis 
A sensitivity analysis will be conducted to assess methodological, parameter and structural 
uncertainty in the economic evaluation. In particular, the following will be assessed: 
1. The uncertainty around costing assumptions. These may include different sources of 
unit costs and, and varying local estimates. In particularly, we will vary the 
assumptions around the costing of the intervention. We will define worse and best case 
scenarios, such as full capacity or low attendance in classes, and delivery of classes in 
a community setting. Further class size considerations are described in section IIIv. 
2. The uncertainty surrounding missing data and assumptions around dealing with 
implausible resource use values. 
3. The uncertainty around the impact of the multiple imputation model. If feasible, we 
will attempt a model structure where all clinical outcomes are also imputed, EQ-5D 
domains are imputed, and resource use by time point is imputed. These models may 
not be feasible.  
4. We will consider the proportion of patients in standard care and the intervention, 
requiring additional physiotherapy and consider if of value to vary the proportion of 
additional physio required. 
 
These analyses will be conducted as one-way or scenario analyses, but if data allow, and if of 
relevance, we may extend this to a probabilistic analysis. 
 
i. Presentation of results 
A table will be presented with the average cost of delivery of the intervention and all other 
mean cost categories, per trial group (treatment or standard care), per centre, at 12 months 
postoperative. These will include all raw available data and imputed and adjusted cost 
categories.  
The primary economic result will be the incremental net monetary benefit (INMB) statistic, 
from an NHS and PSS perspective, with a range of values for the societal willingness to pay 
for a QALY (i.e. a year of life in perfect health). The INMB shows the incremental benefit, 
expressed in monetary units, less the incremental costs of our intervention over the standard 
care group. This requires a defined WTP threshold for the conversion of benefits (QALYs) 
ARENA trial 2017 
 
ARENA SHEAP version 1, 07/09/2017 Page 30 
 
into monetary units. We will consider the societal willingness to pay (WTP) thresholds 
recommended by the National Institute for Health and Care Excellence (NICE) of £20,000 
and £30,000 per QALY, as well as a published estimate of the observed willingness-to-pay 
(WTP) in the NHS, such as that by Claxton et al.8 
We will also compute the cost-effectiveness acceptability curve (CEAC). The CEAC is a 
method of illustrating uncertainty surrounding cost-effectiveness results by indicating the 
probability that our group physiotherapy intervention is cost-effective over usual care, for a 
range of societal WTP values. 
We will present bootstrapped costs and QALY estimates in a cost-effectiveness plane. If the 
intervention may be dominant (more effective and less costly than standard care) or 
dominated (less effective and more costly than standard care), the probability of dominance 
(proportion of density falling within the relevant quadrant of the CE plane) will be reported.  
V. Other analyses 
a. Serious adverse events 
The serious adverse events (SAEs) will be presented by trial group. We will first present the 
total number of SAEs by trial group. We will then present the number (n=) of patients with at 
a SAE (irrespectively of number of events experienced) by trial group with the percentage 
(from the number of participants randomised in each group). These percentages will be 
compared with Chi-square test or Fisher-exact test. Similarly, we will present the number and 
percentage of participants with 1 SAEs, 2 SAEs, 3 or more SAEs by trial group and we will 
compare those percentages with Chi-square test or Fisher-exact test. 
b. Evaluation of the intervention 
Following the delivery of the intervention, participants will be invited to provide their 
feedback on the intervention and its components.  
For all continuous and score variables we will check distributions using histograms and 
normal plots to examine how close to normality these are before deciding which summary 
statistics to present.  Continuous variables with approximately normal distributions will be 
presented as means and standard deviations (SD).  Continuous variables that we anticipate 
                                                          
8 Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M, Methods for the 
Estimation of the NICE Cost Effectiveness Threshold, Health Technology Assessment, 2013, 19 (14). 
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will not have an approximate normal distribution will be presented as medians and 
interquartile ranges (IQR).  Binary/categorical variables will be presented as number (n=) and 
percentage (%). No imputation will be performed. Missing data will be presented as a 
separate category for categorical variable and the number of participants with missing 
information will be presented for each continuous variable.  
 
Free text fields will be investigated with thematic analysis. Text data will be imported into 
Excel and then collated and coded into themes by a member of the research team. These 
themes will then be reviewed by a second member of the research team, and any 
discrepancies resolved through discussion.  
c. Further exploratory investigation 
Class size and the investigation of composition of intervention class effect 
We will explore the impact of class composition on LEFS at 12 months by stratifying patients 
assigned to the intervention group into new categories defined by the number of participants 
in the intervention classes they attended. As this is an exploratory analysis, the classification 
will depend on what we observe: for example, a participant could be classified as having 
“only attended classes with more than 5 patients”; “only attended classes with less than 5 
patients”; or “having attended some classes with less than 5 patients”. Those assigned to the 
usual care group will be considered as one single group as done in all the other analyses 
presented in this document. 
 
Class size is an important variable to consider in the cost effectiveness analyses. The main 
cost categories comprising the delivery of the intervention: booked physiotherapists time and 
room space, are fixed costs: costs incurred irrespective of class size. If classes are not run to 
capacity, the delivery of the intervention would have a higher cost per patient. The primary 
economic analysis result will use the cost of delivery of intervention per patient attending. In 
sensitivity analysis (scenario or probabilistic) we will report the cost-effectiveness results 
using a range of class sizes, including at full capacity. 
 
Sample characteristics and outcomes by participant subgroups 
For descriptive purposes, the baseline characteristics and LEFS at 12 months will be 
described and compared by place of recruitment (Southmead vs Emersons Green). They will 
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also be reported by place of intervention delivery (Southmead <11/07/2016 vs Cosham 
≥11/07/2016) for the group of participants randomised to the intervention class. Finally, the 
primary outcome will be compared by method of data collection (postal questionnaire vs 
telephone). The trial is not powered for such analyses which should be considered as an 
exploratory exercise. 
